Eligibility determination for donors of human cells, tissues, and cellular and tissue-based products. Final rule.
The Food and Drug Administration (FDA) is requiring human cell, tissue, and cellular and tissue-based product (HCT/P) establishments to screen and test cell and tissue donors for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases. The agency is amending the current good manufacturing practice (CGMP) and quality system (QS) regulations that apply to HCT/Ps regulated as drugs, medical devices, and/or biological products to clarify the role of the new donor-eligibility regulations in relation to existing CGMP regulations. By preventing the transmission of communicable disease by the wide spectrum of HCT/Ps that are marketed now or may be marketed in the future, the agency's action will improve protection of the public health and increase public confidence in new technologies.
D003140:Communicable Disease Control / Q000331:legislation & jurisprudence*; D003362:Cost-Benefit Analysis; D004608:Eligibility Determination / Q000331:legislation & jurisprudence*; D006801:Humans; D014019:Tissue Donors / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration